Tag: NMPA
Surge in Out-licensing Deals Drive China’s International Pharma Collaborations
China’s out-licensing deals have significantly increased over the last five years, showcasing the country as a source of innovative drugs. The licensing agreements provide...
Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or...
Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints
Disitamab Vedotin Gains Approval in China for its Third Indication
Disitamab Vedotin Gains Approval in China for its Third Indication
China Approves Combination of Enfortumab Vedotin + Pembrolizumab for the Treatment...
China Approves Combination of Enfortumab Vedotin + Pembrolizumab for the Treatment of Advanced Bladder Cancer
BioRay’s IND Application for BRY812, Accepted by the China National Medical...
The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors (Acceptance No. CXSL2300366). The investigational drug is being developed by Shanghai-based BioRay Pharmaceutical Co.
